<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00305630</url>
  </required_header>
  <id_info>
    <org_study_id>IND 64263</org_study_id>
    <nct_id>NCT00305630</nct_id>
  </id_info>
  <brief_title>Neovascular Age Related Macular Degeneration (AMD), Periocular Corticosteroids, and Photodynamic Therapy (PDT)</brief_title>
  <official_title>Neovascular Age Related Macular Degeneration, Periocular Corticosteroids, and Photodynamic Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <brief_summary>
    <textblock>
      Randomized controlled clinical trial of periocular corticosteroids as adjunctive therapy to
      photodynamic therapy (PDT) for patients with neovascular age-related macular degeneration
      (AMD). Patients undergoing PDT are randomized to either a periocular corticosteroid injection
      with 40 mg of triamcinolone acetonide or observation just prior to PDT. Patients are followed
      for 6 months. Primary outcome is leakage from choroidal neovascularization (CNV) at 3 months
      on fluorescein angiography.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2002</start_date>
  <completion_date>November 2005</completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fluorescein leakage from choroidal neovascularization on fluorescein angiography at 3 months after randomization.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
  </secondary_outcome>
  <enrollment>100</enrollment>
  <condition>Choroidal Neovascularization</condition>
  <condition>Age-Related Macular Degeneration</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Periocular injection of triamcinolone acetonide 40mg</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Active choroidal neovascularization

          -  Age related macular degeneration

          -  Visual acuity 20/20 to 20/400

        Exclusion Criteria:

          -  Neovascular lesion &gt;6500 microns is greatest linear diameter

          -  More than one prior photodynamic therapy treatment

          -  Receiving systemic corticosteroids

          -  Intraocular pressure &gt; 21 mm Hg or glaucoma medication use

          -  History of glaucoma or history of ocular hypertension
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Douglas A Jabs, MD, MBA</last_name>
    <role>Study Chair</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Neil M Bressler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins Univeristy School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David J Wilson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Univeristy School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health Science Univeristy</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2006</study_first_submitted>
  <study_first_submitted_qc>March 20, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2006</study_first_posted>
  <last_update_submitted>March 20, 2006</last_update_submitted>
  <last_update_submitted_qc>March 20, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 22, 2006</last_update_posted>
  <keyword>Corticosteroids</keyword>
  <keyword>Triamcinolone</keyword>
  <keyword>Photodynamic therapy</keyword>
  <keyword>Choroidal neovascularization</keyword>
  <keyword>Age-related macular degeneration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Neovascularization, Pathologic</mesh_term>
    <mesh_term>Choroidal Neovascularization</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

